Why ImmunityBio, Inc. (IBRX) stock fell 17.7% on Monday, November 9, 2026

ImmunityBio, Inc. (IBRX) closed at $7.11, down 17.66% on Monday, November 9, 2026, on volume of 44,715,089 shares (3.9× its 3-month average); market value about $7.50B.

What happened: primary sources

Events Nexqual found for IBRX on Monday, November 9, 2026 or the trading day before (November 6, 2026):

• Nov 9, 2026: Reported Q3 2026 results: EPS −$0.18 vs consensus −$0.05 (miss), revenue $48.8M vs consensus $59.2M (miss). source
• Nov 9, 2026: SEC 8-K: Regulation FD disclosure source

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on IBRX

IBRX stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Earnings report: IBRX results, November 9, 2026. Other big moves that day: November 9, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:24 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 10, 2026 at 16:24 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt